Moderna Raises Its 2026 Sales Growth Forecast to 15%–25%

Moderna expects 2026 sales to grow 15% to 25%, up from its earlier forecast of no more than 10%, per third-quarter results released November 6, 2026. Its forecast for running costs, under standard US accounting rules, improved by about $0.2 billion, meaning lower spending. A second-quarter filing expected about 55% of second-half (July–December) sales to arrive in the third quarter.